Informations générales (source: ClinicalTrials.gov)
Validation of the Use of the "ELN 2022" Risk Stratification System in HLA MENAFC Patients Newly Diagnosed With Acute Myeloid Leukemia
Observational
Centre Hospitalier Universitaire de Nice (Voir sur ClinicalTrials)
août 2024
janvier 2025
23 juillet 2024
"In daily clinical practice, 2022 ELN guidelines were used to predict response to
conventional treatment and to guide the need for allogenic stem cell transplantation.
But, the team has to underline that ELN guidelines are mainly reflective of relatively
young Caucasian patients. Few studies have compared 2017 and 2022 ELN in ethnicity
cohorts to evaluate the potential prognostic value of this new criteria in these types of
population. For example, with the 2022 ELN guidelines, the disease-free surviva) and the
overall survival of African American < 60 y.o were not statistically different between
intermediate and adverse groups (p=0.30, p=0,46). There were not a significant difference
between favorable and intermediate groups in DFS (p=0.42, p=0.42) respectively in African
American and Hispanic patients or in OS (p=0.67) in Hispanic patients. Is the 2022 ELN
applicable to all ethnic subgroups? To date, no studies have examined and validated its
applicability in Middle Eastern or North Coast of Africa (MENAFC) patients."
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL NOVO | OUIS TARHI Kahina | 18/09/2025 17:50:04 | Contacter | ||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CHU NICE - 0600 - Nice - Alpes Maritimes - France | Thomas CLUZEA | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Newly diagnosed AML
- At least 18 yo
- MENAFC (Middle East ern of North Coast of Africa) patients with HLA HLA > 50%
- ECOG performance status of 0,1,2,3"
- Newly diagnosed AML
- At least 18 yo
- MENAFC (Middle East ern of North Coast of Africa) patients with HLA HLA > 50%
- ECOG performance status of 0,1,2,3"
- Acute promyelocytic leukemia
- Patients alive at the start of the study who did not receive study information or
who objected to the collection of data"